207 related articles for article (PubMed ID: 38665722)
1. Evaluating the Efficacy and Safety of Tirzepatide on Glycaemic and Non-glycaemic Outcomes in Diabetes: A Systematic Review of Meta-Analyses.
Kaore S; B B; Khasbage S; Atal S
Cureus; 2024 Mar; 16(3):e56939. PubMed ID: 38665722
[TBL] [Abstract][Full Text] [Related]
2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
3. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
4. Tirzepatide: A Review in Type 2 Diabetes.
France NL; Syed YY
Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
[TBL] [Abstract][Full Text] [Related]
7. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.
Tang Y; Zhang L; Zeng Y; Wang X; Zhang M
Front Pharmacol; 2022; 13():1016639. PubMed ID: 36569320
[No Abstract] [Full Text] [Related]
9. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
Yu D; Shen S; Zhang J; Wang Q
Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
[TBL] [Abstract][Full Text] [Related]
11. Is tirzepatide 15 mg the preferred treatment strategy for type 2 diabetes? A meta-analysis and trial-sequence-analysis.
Yang XY; Yin S; Yu YF; Hu G; Hang FZ; Zhou ML; Liu P; Jian WX
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7164-7179. PubMed ID: 37606127
[TBL] [Abstract][Full Text] [Related]
12. Tirzepatide for type 2 diabetes.
Anderson SL; Marrs JC
Drugs Context; 2023; 12():. PubMed ID: 37664792
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
14. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
15. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.
Bhagavathula AS; Vidyasagar K; Tesfaye W
Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681215
[TBL] [Abstract][Full Text] [Related]
17. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
Nowak M; Nowak W; Grzeszczak W
Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management.
Sinha R; Papamargaritis D; Sargeant JA; Davies MJ
J Obes Metab Syndr; 2023 Mar; 32(1):25-45. PubMed ID: 36750526
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
Meng Z; Yang M; Wen H; Zhou S; Xiong C; Wang Y
Front Endocrinol (Lausanne); 2023; 14():1121387. PubMed ID: 37051199
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
Kadowaki T; Chin R; Ozeki A; Imaoka T; Ogawa Y
Lancet Diabetes Endocrinol; 2022 Sep; 10(9):634-644. PubMed ID: 35914542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
